Agner, K. Verdoperoxidase: a ferment isolated from leucocytes. Acta Chem. Scand., 1941, 2(Suppl 8), 1-62.
Harrison, J.E.; Schultz, J. Studies on the chlorinating activity of myeloperoxidase. J. Biol. Chem., 1976, 251(5), 1371-1374.
Klebanoff, S.J. Myeloperoxidase: friend and foe. J. Leukoc. Biol., 2005, 77(5), 598-625.
Pattison, D.I.; Davies, M.J. Kinetic analysis of the reactions of hypobromous acid with protein components: implications for cellular damage and use of 3-bromotyrosine as a marker of oxidative stress. Biochemistry, 2004, 43(16), 4799-4809.
Henderson, J.P.; Byun, J.; Takeshita, J.; Heinecke, J.W. Phagocytes produce 5-chlorouracil and 5-bromouracil, two mutagenic products of myeloperoxidase, in human inflammatory tissue. J. Biol. Chem., 2003, 278(26), 23522-23528.
Karakas, M.; Koenig, W. Myeloperoxidase production by macrophage and risk of atherosclerosis. Curr. Atheroscler. Rep., 2012, 14(3), 277-283.
Taguchi, J.; Miyazaki, Y.; Tsutsumi, C.; Sawayama, Y.; Ando, K.; Tsushima, H.; Fukushima, T.; Hata, T.; Yoshida, S.; Kuriyama, K.; Honda, S.; Jinnai, I.; Mano, H.; Tomonaga, M. Expression of the myeloperoxidase gene in AC133 positive leukemia cells relates to the prognosis of acute myeloid leukemia. Leuk. Res., 2006, 30(9), 1105-1112.
Gray, E.; Thomas, T.L.; Betmouni, S.; Scolding, N.; Love, S. Elevated myeloperoxidase activity in white matter in multiple sclerosis. Neurosci. Lett., 2008, 444(2), 195-198.
Ximenes, V.F.; Paino, I.M.; Faria-Oliveira, O.M.; Fonseca, L.M.; Brunetti, I.L. Indole ring oxidation by activated leukocytes prevents the production of hypochlorous acid. Braz. J. Med. Biol. Res., 2005, 38(11), 1575-1583.
Malle, E.; Furtmuller, P.G.; Sattler, W.; Obinger, C. Myeloperoxidase: a target for new drug development? Br. J. Pharmacol., 2007, 152(6), 838-854.
Koch, C. Effect of sodium azide upon normal and pathological granulocyte function. Acta Pathol. Microbiol. Scand. B Microbiol. Immunol., 1974, 82(1), 136-142.
Bainton, D.F.; Ullyot, J.L.; Farquhar, M.G. The development of neutrophilic polymorphonuclear leukocytes in human bone marrow. J. Exp. Med., 1971, 134(4), 907-934.
Dunn, W.B.; Hardin, J.H.; Spicer, S.S. Ultrastructural localization of myeloperoxidase in human neutrophil and rabbit heterophil and eosinophil leukocytes. Blood, 1968, 32(6), 935-944.
Odell, E.W.; Segal, A.W. The bactericidal effects of the respiratory burst and the myeloperoxidase system isolated in neutrophil cytoplasts. Biochim. Biophys. Acta, 1988, 971(3), 266-274.
Banerjee, S.; Stampler, J.; Furtmuller, P.G.; Obinger, C. Conformational and thermal stability of mature dimeric human myeloperoxidase and a recombinant monomeric form from CHO cells. Biochim. Biophys. Acta, 2011, 1814(2), 375-387.
Van Antwerpen, P.; Slomianny, M.C.; Boudjeltia, K.Z.; Delporte, C.; Faid, V.; Calay, D.; Rousseau, A.; Moguilevsky, N.; Raes, M.; Vanhamme, L.; Furtmuller, P.G.; Obinger, C.; Vanhaeverbeek, M.; Neve, J.; Michalski, J.C. Glycosylation pattern of mature dimeric leukocyte and recombinant monomeric myeloperoxidase: glycosylation is required for optimal enzymatic activity. J. Biol. Chem., 2010, 285(21), 16351-16359.
Stampler, J.; Bellei, M.; Soudi, M.; Gruber, C.; Battistuzzi, G.; Furtmuller, P.G.; Obinger, C. Manipulating the proximal triad His-Asn-Arg in human myeloperoxidase. Arch. Biochem. Biophys., 2011, 516(1), 21-28.
Van Antwerpen, P.; Zouaoui Boudjeltia, K. Rational drug design applied to myeloperoxidase inhibition. Free Rad. Res., 2015, 49(6), 711-720.
Arnhold, J.; Flemmig, J. Human myeloperoxidase in innate and acquired immunity. Arch. Biochem. Biophys., 2010, 500(1), 92-106.
Griffin, F.M. Jr.; Griffin, J.A.; Leider, J.E.; Silverstein, S.C. Studies on the mechanism of phagocytosis. I. Requirements for circumferential attachment of particle-bound ligands to specific receptors on the macrophage plasma membrane. J. Exp. Med., 1975, 142(5), 1263-1282.
Davies, M.J. Myeloperoxidase-derived oxidation: mechanisms of biological damage and its prevention. J. Clin. Biochem. Nutr., 2011, 48(1), 8-19.
Zederbauer, M.; Furtmuller, P.G.; Brogioni, S.; Jakopitsch, C.; Smulevich, G.; Obinger, C. Heme to protein linkages in mammalian peroxidases: impact on spectroscopic, redox and catalytic properties. Nat. Prod. Rep., 2007, 24(3), 571-584.
Furtmüller, P.G.; Burner, U.; Obinger, C. Reaction of myeloperoxidase compound I with chloride, bromide, iodide, and thiocyanate. Biochemistry, 1998, 37(51), 17923-17930.
Burtis, C.A.; Ashwood, E.R.; Bruns, D.E.; Tietz, N.W. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 4th ed. Saunders: St. Louis, Mo. 2006.
Agner, K. Detoxicating effect of verdoperoxidase on toxins. Nature, 1947, 159(4034), 271.
Agner, K. Studies on peroxidative detoxification of purified diphtheria toxin. J. Exp. Med., 1950, 92(4), 337-347.
Klebanoff, S.J.; Green, W.L. Degradation of thyroid hormones by phagocytosing human leukocytes. J. Clin. Iinvest., 1973, 52(1), 60-72.
Klebanoff, S.J. Estrogen binding by leukocytes during phagocytosis. J. Exp. Med., 1977, 145(4), 983-998.
Fiedler, T.J.; Davey, C.A.; Fenna, R.E. X-ray crystal structure and characterization of halide-binding sites of human myeloperoxidase at 1.8 A resolution. J. Biol. Chem., 2000, 275(16), 11964-11971.
Arnhold, J.; Monzani, E.; Furtmüller, P.G.; Zederbauer, M.; Casella, L.; Obinger, C. Kinetics and thermodynamics of halide and nitrite oxidation by mammalian heme peroxidases. Eur. J. Inorg. Chem., 2006, 2006(19), 3801-3811.
Ximenes, V.F.; Maghzal, G.J.; Turner, R.; Kato, Y.; Winterbourn, C.C.; Kettle, A.J. Serotonin as a physiological substrate for myeloperoxidase and its superoxide-dependent oxidation to cytotoxic tryptamine-4,5-dione. Biochem. J., 2010, 425(1), 285-293.
Jantschko, W.; Georg Furtmuller, P.; Zederbauer, M.; Lanz, M.; Jakopitsch, C.; Obinger, C. Direct conversion of ferrous myeloperoxidase to compound II by hydrogen peroxide: an anaerobic stopped-flow study. Biochem. Biophys. Res. Commun., 2003, 312(2), 292-298.
Soubhye, J.; Prevost, M.; Van Antwerpen, P.; Zouaoui Boudjeltia, K.; Rousseau, A.; Furtmuller, P.G.; Obinger, C.; Vanhaeverbeek, M.; Ducobu, J.; Neve, J.; Gelbcke, M.; Dufrasne, F.O. Structure-based design, synthesis, and pharmacological evaluation of 3- (aminoalkyl)-5-fluoroindoles as myeloperoxidase inhibitors. J. Med. Chem., 2010, 53(24), 8747-8759.
Poulos, T.L.; Kraut, J. The stereochemistry of peroxidase catalysis. J. Biol. Chem., 1980, 255(17), 8199-8205.
Furtmüller, P.G.; Arnhold, J.; Jantschko, W.; Pichler, H.; Obinger, C. Redox properties of the couples compound I/compound II and compound II/native enzyme of human myeloperoxidase. Biochem. Biophys. Res. Commun., 2003, 301(2), 551-557.
Arnhold, J.; Furtmuller, P.G.; Obinger, C. Redox properties of myeloperoxidase. Redox. Rep., 2003, 8(4), 179-186.
Arnhold, J.; Furtmuller, P.G.; Regelsberger, G.; Obinger, C. Redox properties of the couple compound I/native enzyme of myeloperoxidase and eosinophil peroxidase. Eur. J. Biochem., 2001, 268(19), 5142-5148.
Delporte, C.; Franck, T.; Noyon, C.; Dufour, D.; Rousseau, A.; Madhoun, P.; Desmet, J.M.; Serteyn, D.; Raes, M.; Nortier, J.; Vanhaeverbeek, M.; Moguilevsky, N.; Neve, J.; Vanhamme, L.; Van Antwerpen, P.; Zouaoui Boudjeltia, K. Simultaneous measurement of protein-bound 3-chlorotyrosine and homocitrulline by LC-MS/MS after hydrolysis assisted by microwave: application to the study of myeloperoxidase activity during hemodialysis. Talanta, 2012, 99, 603-609.
Cheng, G.; Salerno, J.C.; Cao, Z.; Pagano, P.J.; Lambeth, J.D. Identification and characterization of VPO1, a new animal heme-containing peroxidase. Free Radic. Biol. Med., 2008, 45(12), 1682-1694.
Li, H.; Cao, Z.; Moore, D.R.; Jackson, P.L.; Barnes, S.; Lambeth, J.D.; Thannickal, V.J.; Cheng, G. Microbicidal activity of vascular peroxidase 1 in human plasma via generation of hypochlorous acid. Infect. Immun., 2012, 80(7), 2528-2537.
Rosamond, W.; Flegal, K.; Furie, K.; Go, A.; Greenlund, K.; Haase, N.; Hailpern, S.M.; Ho, M.; Howard, V.; Kissela, B.; Kittner, S.; Lloyd-Jones, D.; McDermott, M.; Meigs, J.; Moy, C.; Nichol, G.; O'Donnell, C.; Roger, V.; Sorlie, P.; Steinberger, J.; Thom, T.; Wilson, M.; Hong, Y. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 2008, 117(4), e25-146.
Grundy, S.M. Cholesterol and coronary heart disease. A new era. JAMA, 1986, 256(20), 2849-2858.
Libby, P.; Ridker, P.M.; Hansson, G.K. Progress and challenges in translating the biology of atherosclerosis. Nature, 2011, 473(7347), 317-325.
Heinecke, J.W. Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis, 1998, 141(1), 1-15.
Delporte, C.; Van Antwerpen, P.; Vanhamme, L.; Roumeguere, T.; Zouaoui Boudjeltia, K. Low-density lipoprotein modified by myeloperoxidase in inflammatory pathways and clinical studies. Mediators Inflamm., 2013, 2013, 18.
Daugherty, A.; Dunn, J.L.; Rateri, D.L.; Heinecke, J.W. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J. Clin. Invest., 1994, 94(1), 437-444.
Hazen, S.L.; Heinecke, J.W. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J. Clin. Invest., 1997, 99(9), 2075-2081.
Malle, E.; Waeg, G.; Schreiber, R.; Grone, E.F.; Sattler, W.; Grone, H.J. Immunohistochemical evidence for the myeloperoxidase/H2O2/halide system in human atherosclerotic lesions: colocalization of myeloperoxidase and hypochlorite-modified proteins. Eur. J. Biochem., 2000, 267(14), 4495-4503.
Haslacher, H.; Perkmann, T.; Gruenewald, J.; Exner, M.; Endler, G.; Scheichenberger, V.; Wagner, O.; Schillinger, M. Plasma myeloperoxidase level and peripheral arterial disease. Eur. J. Clin. Invest., 2012, 42(5), 463-469.
Nicholls, S.J.; Hazen, S.L. Myeloperoxidase, modified lipoproteins, and atherogenesis. J. Lipid Res., 2009, 50(Suppl), S346-351.
Kannel, W.B.; Castelli, W.P.; Gordon, T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann. Intern. Med., 1979, 90(1), 85-91.
Roman, R.M.; Wendland, A.E.; Polanczyk, C.A. Myeloperoxidase and coronary arterial disease: from research to clinical practice. Arq. Bras. Cardiol., 2008, 91(1), e11-19.
Wu, M.C.; Ho, H.I.; Lee, T.W.; Wu, H.L.; Lo, J.M. In vivo examination of 111In-bis- 5HT-DTPA to target myeloperoxidase in atherosclerotic ApoE knockout mice. J. Drug Target, 2012, 20(7), 605-614.
Itabe, H. Oxidative modification of LDL: its pathological role in atherosclerosis. Clin. Rev. Allergy Immunol., 2009, 37(1), 4-11.
Abu-Soud, H.M.; Hazen, S.L. Nitric oxide is a physiological substrate for mammalian peroxidases. J. Biol. Chem., 2000, 275(48), 37524-37532.
Huang, Y.; Wu, Z.; Riwanto, M.; Gao, S.; Levison, B.S.; Gu, X.; Fu, X.; Wagner, M.A.; Besler, C.; Gerstenecker, G.; Zhang, R.; Li, X.M.; Di Donato, A.J.; Gogonea, V.; Tang, W.H.; Smith, J.D.; Plow, E.F.; Fox, P.L.; Shih, D.M.; Lusis, A.J.; Fisher, E.A.; Di Donato, J.A.; Landmesser, U.; Hazen, S.L. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J. Clin. Invest., 2013, 123(9), 3815-3828.
Fu, X.; Kassim, S.Y.; Parks, W.C.; Heinecke, J.W. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J. Biol. Chem., 2001, 276(44), 41279-41287.
Sugiyama, S.; Okada, Y.; Sukhova, G.K.; Virmani, R.; Heinecke, J.W.; Libby, P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am. J. Pathol., 2001, 158(3), 879-891.
Compston, A.; Coles, A. Multiple sclerosis. Lancet, 2002, 359(9313), 1221-1231.
Nagra, R.M.; Becher, B.; Tourtellotte, W.W.; Antel, J.P.; Gold, D.; Paladino, T.; Smith, R.A.; Nelson, J.R.; Reynolds, W.F. Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis. J. Neuroimmunol., 1997, 78(1-2), 97-107.
Green, P.S.; Mendez, A.J.; Jacob, J.S.; Crowley, J.R.; Growdon, W.; Hyman, B.T.; Heinecke, J.W. Neuronal expression of myeloperoxidase is increased in Alzheimer's disease. J. Neurochem., 2004, 90(3), 724-733.
Choi, D.K.; Pennathur, S.; Perier, C.; Tieu, K.; Teismann, P.; Wu, D.C.; Jackson-Lewis, V.; Vila, M.; Vonsattel, J.P.; Heinecke, J.W.; Przedborski, S. Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. J. Neurosci., 2005, 25(28), 6594-6600.
D'Agati, V. Antineutrophil cytoplasmic antibody and vasculitis: much more than a disease marker. J. Clin. Invest., 2002, 110(7), 919-921.
Hoshino, A.; Nagao, T.; Nagi-Miura, N.; Ohno, N.; Yasuhara, M.; Yamamoto, K.; Nakayama, T.; Suzuki, K. MPOANCA induces IL-17 production by activated neutrophils in vitro via classical complement pathway-dependent manner. J. Autoimmun., 2008, 31(1), 79-89.
Anders, H.J.; Wiebecke, B.; Haedecke, C.; Sanden, S.; Combe, C.; Schlondorff, D. MPO-ANCA-Positive crescentic glomerulonephritis: a distinct entity of scleroderma renal disease? Am. J. Kidney Dis., 1999, 33(4), e3.
Ohtani, H.; Wakui, H.; Komatsuda, A.; Chyzh, K.A.; Hatakeyama, T.; Masai, R.; Okuyama, S.; Togashi, M.; Sawada, K. Differences between myeloperoxidase-specific and - nonspecific P-ANCA-associated renal disease. Ren. Fail., 2007, 29(2), 183-187.
Saeki, T.; Kuroda, T.; Morita, T.; Suzuki, K.; Arakawa, M.; Kawasaki, K. Significance of myeloperoxidase in rapidly progressive glomerulonephritis. Am. J. Kidney Dis., 1995, 26(1), 13-21.
Malle, E.; Woenckhaus, C.; Waeg, G.; Esterbauer, H.; Grone, E.F.; Grone, H.J. Immunological evidence for hypochlorite-modified proteins in human kidney. Am. J. Pathol., 1997, 150(2), 603-615.
Ames, B.N. Endogenous DNA damage as related to cancer and aging. Mutat. Res., 1989, 214(1), 41-46.
Esterbauer, H.; Eckl, P.; Ortner, A. Possible mutagens derived from lipids and lipid precursors. Mutat. Res., 1990, 238(3), 223-233.
Henderson, J.P.; Byun, J.; Williams, M.V.; Mueller, D.M.; McCormick, M.L.; Heinecke, J.W. Production of brominating intermediates by myeloperoxidase. A transhalogenation pathway for generating mutagenic nucleobases during inflammation. J. Biol. Chem., 2001, 276(11), 7867-7875.
Pal, B.C.; Cumming, R.B.; Walton, M.F.; Preston, R.J. Environmental pollutant 5-chlorouracil is incorporated in mouse liver and testes DNA. Mutat. Res., 1981, 91(4-5), 395-401.
Hofstra, A.H.; Uetrecht, J.P. Myeloperoxidase-mediated activation of xenobiotics by human leukocytes. Toxicology, 1993, 82(1-3), 221-242.
Rojas, M.; Godschalk, R.; Alexandrov, K.; Cascorbi, I.; Kriek, E.; Ostertag, J.; Van Schooten, F.J.; Bartsch, H. Myeloperoxidase-463A variant reduces benzo[a]pyrene diol epoxide DNA adducts in skin of coal tar treated patients. Carcinogenesis, 2001, 22(7), 1015-1018.
Johnson, E.S.; Langard, S.; Lin, Y.S. A critique of benzene exposure in the general population. Sci. Total Environ., 2007, 374(2-3), 183-198.
Le Marchand, L.; Seifried, A.; Lum, A.; Wilkens, L.R. Association of the myeloperoxidase -463G->a polymorphism with lung cancer risk. Cancer Epidemiol. Biomarkers Prev., 2000, 9(2), 181-184.
Schabath, M.B.; Spitz, M.R.; Delclos, G.L.; Gunn, G.B.; Whitehead, L.W.; Wu, X. Association between asbestos exposure, cigarette smoking, myeloperoxidase (MPO) genotypes, and lung cancer risk. Am. J. Ind. Med., 2002, 42(1), 29-37.
Wu, X.; Schabath, M.B.; Spitz, M.R. Myeloperoxidase promoter region polymorphism and lung cancer risk. Methods Mol. Med., 2003, 75, 121-133.
Feyler, A.; Voho, A.; Bouchardy, C.; Kuokkanen, K.; Dayer, P.; Hirvonen, A.; Benhamou, S. Point: myeloperoxidase -463G -< a polymorphism and lung cancer risk. Cancer Epidemiol. Biomarkers Prev., 2002, 11(12), 1550-1554.
Saed, G.M.; Ali-Fehmi, R.; Jiang, Z.L.; Fletcher, N.M.; Diamond, M.P.; Abu-Soud, H.M.; Munkarah, A.R. Myeloperoxidase serves as a redox switch that regulates apoptosis in epithelial ovarian cancer. Gynecol. Oncol., 2010, 116(2), 276-281.
Ramsaransing, G.; Teelken, A.; Prokopenko, V.M.; Arutjunyan, A.V.; De Keyser, J. Low leucocyte myeloperoxidase activity in patients with multiple sclerosis. J. Neurol. Neurosurg. Psychiat., 2003, 74(7), 953-955.
Cascorbi, I.; Henning, S.; Brockmoller, J.; Gephart, J.; Meisel, C.; Muller, J.M.; Loddenkemper, R.; Roots, I. Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant-463A of the myeloperoxidase gene. Cancer Res., 2000, 60(3), 644-649.
Hung, R.J.; Boffetta, P.; Brennan, P.; Malaveille, C.; Gelatti, U.; Placidi, D.; Carta, A.; Hautefeuille, A.; Porru, S. Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk. Carcinogenesis, 2004, 25(6), 973-978.
Pakakasama, S.; Chen, T.T.; Frawley, W.; Muller, C.; Douglass, E.C.; Tomlinson, G.E. Myeloperoxidase promotor polymorphism and risk of hepatoblastoma. Int. J. Cancer, 2003, 106(2), 205-207.
Lee, J.S.; Oh, T.Y.; Ahn, B.O.; Cho, H.; Kim, W.B.; Kim, Y.B.; Surh, Y.J.; Kim, H.J.; Hahm, K.B. Involvement of oxidative stress in experimentally induced reflux esophagitis and Barrett's esophagus: clue for the chemoprevention of esophageal carcinoma by antioxidants. Mutat. Res., 2001, 480-481, 189-200.
Hiramatsu, K.; Rosen, H.; Heinecke, J.W.; Wolfbauer, G.; Chait, A. Superoxide initiates oxidation of low density lipoprotein by human monocytes. Arteriosclerosis, 1987, 7(1), 55-60.
Malvezzi, A.; Queiroz, R.; de Rezende, L.; Augusto, O.; Amaral, T. MPO Inhibitors selected by virtual screening. Mol. Informatics, 2011, 30(6-7), 605-613.
Tiden, A.K.; Sjogren, T.; Svensson, M.; Bernlind, A.; Senthilmohan, R.; Auchere, F.; Norman, H.; Markgren, P.O.; Gustavsson, S.; Schmidt, S.; Lundquist, S.; Forbes, L.V.; Magon, N.J.; Paton, L.N.; Jameson, G.N.; Eriksson, H.; Kettle, A.J. 2-thioxanthines are mechanism-based inactivators of myeloperoxidase that block oxidative stress during inflammation. J. Biol. Chem., 2011, 286(43), 37578-37589.
Carpino, P.; Conn, E.; Dow, R.; Dowling, M.; Hepworth, D.; Kung, D.; Orr, S.; Rocke, B.; Ruggeri, R.; Sammons, M.; Warmus, J.; Zhang, Y. 2-Thiopyrimidinones WO2013 068875 A1 2013.
Lambeth, J.D.; Ganesh, T.; Smith, S.M.; Sun, A. Quinazoline derivatives, compositions, and uses related thereto. WO/2013/181135, 2013.
Soubhye, J.; Aldib, I.; Prevost, M.; Betina, E.; Gelbcke, M.; Podrecca, M.; Conotte, R.; Colet, J.M.; Furtmuller, P.G.; Delporte, C.; Rousseau, A.; Vanhaerverbeek, M.; Neve, J.; Obinger, C.; Zouaoui Boudjeltia, K.; Van Antwerpen, P.; Dufrasne, F. Hybrid molecules inhibiting myeloperoxidase activity and serotonin reuptake: a possible new approach of major depressive disorders with inflammatory syndrome. J. Pharm. Pharmacol., 2014.
van Zyl, J.M.; Basson, K.; Uebel, R.A.; van der Walt, B.J. Isoniazid-mediated irreversible inhibition of the myeloperoxidase antimicrobial system of the human neutrophil and the effect of thyronines. Biochem. Pharmacol., 1989, 38(14), 2363-2373.
Burner, U.; Obinger, C.; Paumann, M.; Furtmuller, P.G.; Kettle, A.J. Transient and steady-state kinetics of the oxidation of substituted benzoic acid hydrazides by myeloperoxidase. J. Biol. Chem., 1999, 274(14), 9494-9502.
Bloomer, J.C.; Woods, F.R.; Haddock, R.E.; Lennard, M.S.; Tucker, G.T. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br. J. Clin. Pharmacol., 1992, 33(5), 521-523.
Soubhye, J.; Aldib, I.; Elfving, B.; Gelbcke, M.; Furtmuller, P.G.; Podrecca, M.; Conotte, R.; Colet, J.M.; Rousseau, A.; Reye, F.; Sarakbi, A.; Vanhaeverbeek, M.; Kauffmann, J.M.; Obinger, C.; Neve, J.; Prevost, M.; Zouaoui Boudjeltia, K.; Dufrasne, F.; Van Antwerpen, P. Design, synthesis, and structure-activity relationship studies of novel 3-alkylindole derivatives as selective and highly potent myeloperoxidase inhibitors. J. Med. Chem., 2013, 56(10), 3943-3958.
Shiba, Y.; Kinoshita, T.; Chuman, H.; Taketani, Y.; Takeda, E.; Kato, Y.; Naito, M.; Kawabata, K.; Ishisaka, A.; Terao, J.; Kawai, Y. Flavonoids as substrates and inhibitors of myeloperoxidase: molecular actions of aglycone and metabolites. Chem. Res. Toxicol., 2008, 21(8), 1600-1609.
Ikeda-Saito, M.; Shelley, D.A.; Lu, L.; Booth, K.S.; Caughey, W.S.; Kimura, S. Salicylhydroxamic acid inhibits myeloperoxidase activity. J. Biol. Chem., 1991, 266(6), 3611-3616.
Kinghorn, D. Principles of Drug Discovery, 2007, pp 13-28.
Heinecke, J.W.; Li, W.; Daehnke, H.L. 3rd; Goldstein, J.A. Dityrosine, a specific marker of oxidation, is synthesized by the myeloperoxidase-hydrogen peroxide system of human neutrophils and macrophages. J. Biol. Chem., 1993, 268(6), 4069-4077.
Capeillere-Blandin, C. Oxidation of guaiacol by myeloperoxidase: a two-electron-oxidized guaiacol transient species as a mediator of NADPH oxidation. Biochem. J., 1998, 33(Pt 2), 395-404.
Kato, Y.; Nagao, A.; Terao, J.; Osawa, T. Inhibition of myeloperoxidase-catalyzed tyrosylation by phenolic antioxidants in vitro. Biosci. Biotechnol. Biochem., 2003, 67(5), 1136-1139.
Bozeman, P.M.; Learn, D.B.; Thomas, E.L. Assay of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase. J. Immunol. Methods, 1990, 126(1), 125-133.
Kettle, A.J.; Winterbourn, C.C. Mechanism of inhibition of myeloperoxidase by anti-inflammatory drugs. Biochem. Pharmacol., 1991, 41(10), 1485-1492.
Sliskovic, I.; Abdulhamid, I.; Sharma, M.; Abu-Soud, H.M. Analysis of the mechanism by which tryptophan analogs inhibit human myeloperoxidase. Free Radic. Biol. Med., 2009, 47(7), 1005-1013.
van der Does, A.M.; Hensbergen, P.J.; Bogaards, S.J.; Cansoy, M.; Deelder, A.M.; van Leeuwen, H.C.; Drijfhout, J.W.; van Dissel, J.T.; Nibbering, P.H. The human lactoferrin-derived peptide hLF1-11 exerts immunomodulatory effects by specific inhibition of myeloperoxidase activity. J. Immunol., 2012, 188(10), 5012-5019.
Weiss, S.J.; Klein, R.; Slivka, A.; Wei, M. Chlorination of taurine by human neutrophils. Evidence for hypochlorous acid generation. J. Clin. Invest., 1982, 70(3), 598-607.
Van Antwerpen, P.; Moreau, P.; Zouaoui Boudjeltia, K.; Babar, S.; Dufrasne, F.; Moguilevsky, N.; Vanhaeverbeek, M.; Ducobu, J.; Neve, J. Development and validation of a screening procedure for the assessment of inhibition using a recombinant enzyme. Talanta, 2008, 75(2), 503-510.
Kettle, A.J.; Winterbourn, C.C. Superoxide modulates the activity of myeloperoxidase and optimizes the production of hypochlorous acid. Biochem. J., 1988, 252(2), 529-536.
Davies, B.; Edwards, S.W. Inhibition of myeloperoxidase by salicylhydroxamic acid. Biochem. J., 1989, 258(3), 801-806.
Maghzal, G.J.; Cergol, K.M.; Shengule, S.R.; Suarna, C.; Newington, D.; Kettle, A.J.; Payne, R.J.; Stocker, R. Assessment of myeloperoxidase activity by the conversion of hydroethidine to 2-chloroethidium. J. Boil. Chem., 2014, 289(9), 5580-5595.
Sokolov, A.V.; Kostevich, V.A.; Kozlov, S.O.; Donskyi, I.S.; Vlasova, II; Rudenko, A.O.; Zakharova, E.T.; Vasilyev, V.B.; Panasenko, O.M. Kinetic method for assaying the halogenating activity of myeloperoxidase based on reaction of celestine blue B with taurine halogenamines. Free Rad. Res., 2015, 49(6), 777-789.
Moguilevsky, N.; Zouaoui Boudjeltia, K.; Babar, S.; Delree, P.; Legssyer, I.; Carpentier, Y.; Vanhaeverbeek, M.; Ducobu, J. Monoclonal antibodies against LDL progressively oxidized by myeloperoxidase react with ApoB-100 protein moiety and human atherosclerotic lesions. Biochem. Biophys. Res. Commun., 2004, 323, (4), 1223-1228.
Neve, J.; Parij, N.; Moguilevsky, N. Inhibition of the myeloperoxidase chlorinating activity by non-steroidal antiinflammatory drugs investigated with a human recombinant enzyme. Eur. J. Pharmacol., 2001, 417(1-2), 37-43.
Van Antwerpen, P.; Dufrasne, F.; Lequeux, M.; Boudjeltia, K.Z.; Lessgyer, I.; Babar, S.; Moreau, P.; Moguilevsky, N.; Vanhaeverbeek, M.; Ducobu, J.; Neve, J. Inhibition of the myeloperoxidase chlorinating activity by non-steroidal antiinflammatory drugs: flufenamic acid and its 5-chloroderivative directly interact with a recombinant human myeloperoxidase to inhibit the synthesis of hypochlorous acid. Eur. J. Pharmacol., 2007, 570(1-3), 235-243.
Regasini, L.O.; Vellosa, J.C.; Silva, D.H.; Furlan, M.; de Oliveira, O.M.; Khalil, N.M.; Brunetti, I.L.; Young, M.C.; Barreiro, E.J.; Bolzani, V.S. Flavonols from Pterogyne nitens and their evaluation as myeloperoxidase inhibitors. Phytochemistry, 2008, 69(8), 1739-1744.
Winterbourn, C.C. Comparative reactivities of various biological compounds with myeloperoxidase-hydrogen peroxide-chloride, and similarity of the oxidant to hypochlorite. Biochim. Biophys. Acta, 1985, 840(2), 204-210.
Pincemail, J.; Deby, C.; Thirion, A.; de Bruyn-Dister, M.; Goutier, R. Human myeloperoxidase activity is inhibited in vitro by quercetin. Comparison with three related compounds. Experientia, 1988, 44(5), 450-453.
Sies, H.; Schewe, T.; Heiss, C.; Kelm, M. Cocoa polyphenols and inflammatory mediators. Am. J. Clin. Nutr., 2005, 81(1 Suppl), 304S-312S.
Krol, W.; Czuba, Z.; Scheller, S.; Paradowski, Z.; Shani, J. Structure-activity relationship in the ability of flavonols to inhibit chemiluminescence. J. Ethnopharmacol., 1994, 41(1-2), 121-126.
Edwards, M.L.; Stemerick, D.M.; Sabol, J.S.; Diekema, K.A.; Dinerstein, R.J. Inhibition of myeloperoxidase release from rat polymorphonuclear leukocytes by a series of azachalcone derivatives. J. Med. Chem., 1994, 37(25), 4357-4362.
Albuquerque, R.; Leal, L.K.; Bandeira, M.; Viana, G.; Rodrigues, L. Chalcones from Myracrodruon urundeuva are efficacious in Guinea Pig ovalbumin-induced allergic conjunctivitis. Brazilian J. Pharmacog., 2011, 21(6), 953-962.
Zeraik, M.L.; Ximenes, V.F.; Regasini, L.O.; Dutra, L.A.; Silva, D.H.; Fonseca, L.M.; Coelho, D.; Machado, S.A.; Bolzani, V.S. 4′-Aminochalcones as novel inhibitors of the chlorinating activity of myeloperoxidase. Curr. Med. Chem., 2012, 19(31), 5405-5413.
Pabuccuoglu, A.; Konyalioglu, S.; Bas, M.; Meral, G.E. The in vitro effects of Hypericum species on human leukocyte myeloperoxidase activity. J. Ethnopharmacol., 2003, 87(1), 89-92.
Schempp, H.; Hippeli, S.; Weiser, D.; Kelber, O.; Elstner, E.F. Comparison of the inhibition of myeloperoxidase-catalyzed hypochlorite formation in vitro and in whole blood by different plant extracts contained in a phytopharmacon treating functional dyspepsia. Arzneimittelforschung, 2004, 54(7), 389-395.
Khalil, N.M.; Pepato, M.T.; Brunetti, I.L. Free radical scavenging profile and myeloperoxidase inhibition of extracts from antidiabetic plants: Bauhinia forficata and Cissus sicyoides. Biol. Res., 2008, 41(2), 165-171.
Nastasijevic, B.; Lazarevic-Pasti, T.; Dimitrijevic-Brankovic, S.; Pasti, I.; Vujacic, A.; Joksic, G.; Vasic, V. Inhibition of myeloperoxidase and antioxidative activity of Gentiana lutea extracts. J. Pharm. Biomed. Anal., 2012, 66, 191-196.
Cavallaro, A.; Ainis, T.; Bottari, C.; Fimiani, V. Effect of resveratrol on some activities of isolated and in whole blood human neutrophils. Physiol. Res., 2003, 52(5), 555-562.
Kohnen, S.; Franck, T.; Van Antwerpen, P.; Boudjeltia, K.Z.; Mouithys-Mickalad, A.; Deby, C.; Moguilevsky, N.; Deby-Dupont, G.; Lamy, M.; Serteyn, D. Resveratrol inhibits the activity of equine neutrophil myeloperoxidase by a direct interaction with the enzyme. J. Agric. Food Chem., 2007, 55(20), 8080-8087.
Diaz-Gonza Lez, M.; Rocasalbas, G.; Francesko, A.; Tourino, S.; Lluis Torres, J.; Tzanov, T. Inhibition of deleterious chronic wound enzymes with plant polyphenols. Biocatal. Biotransformation, 2012, 30(1), 102-110.
Rajagopal, D. Compositions and methods for treatment of cardiovascular disease. 2010.
Boufadi, Y.M.; Soubhye, J.; Riazi, A.; Rousseau, A.; Vanhaeverbeek, M.; Neve, J.; Boudjeltia, K.Z.; Van Antwerpen, P. Characterization and antioxidant properties of six algerian propolis extracts: ethyl acetate extracts inhibit myeloperoxidase activity. Int. J. Mol. Sci., 2014, 15(2), 2327-2345.
Allegra, M.; Furtmuller, P.G.; Regelsberger, G.; Turco-Liveri, M.L.; Tesoriere, L.; Perretti, M.; Livrea, M.A.; Obinger, C. Mechanism of reaction of melatonin with human myeloperoxidase. Biochem. Biophys. Res. Commun., 2001, 282(2), 380-386.
Galijasevic, S.; Abdulhamid, I.; Abu-Soud, H.M. Melatonin is a potent inhibitor for myeloperoxidase. Biochemistry, 2008, 47(8), 2668-2677.
Kleszczynski, K.; Hardkop, L.H.; Fischer, T.W. Differential effects of melatonin as a broad range UV-damage preventive dermato-endocrine regulator. Dermatoendocrinol., 2011, 3(1), 27-31.
Bensalem, S.; Soubhye, J.; Aldib, I.; Bournine, L.; Nguyen, A.T.; Vanhaeverbeek, M.; Rousseau, A.; Boudjeltia, K.Z.; Sarakbi, A.; Kauffmann, J.M.; Neve, J.; Prevost, M.; Stevigny, C.; Maiza-Benabdesselam, F.; Bedjou, F.; Van Antwerpen, P.; Duez, P. Inhibition of myeloperoxidase activity by the alkaloids of Peganum harmala L. (Zygophyllaceae). J. Ethnopharmacol., 2014, 154(2), 361-369.
Van Zyl, A.; Lubbe, S.; Potgieter, A.; Van Zyl, J. The influence of non-steroidal anti-inflammatory and antithyroid agents on myeloperoxidase-catalysed activities of human leucocytes. S. Afr. Med. J., 1979, 55(26), 1082-1087.
Theron, C.N.; Lubbe, S.; Van Zyl, A. Inhibitory effects of non-steroidal anti-inflammatory drugs on human myeloperoxidase. S. Afr. Med. J., 1979, 56(17), 670-675.
Pekoe, G.; Van Dyke, K.; Mengoli, H.; Peden, D.; English, D. Comparison of the effects of antioxidant non-steroidal anti-inflammatory drugs against myeloperoxidase and hypochlorous acid luminol-enhanced chemiluminescence. Agents Actions, 1982, 12(1-2), 232-238.
Pekoe, G.; Van Dyke, K.; Peden, D.; Mengoli, H.; English, D. Antioxidation theory of non-steroidal anti-inflammatory drugs based upon the inhibition of luminol-enhanced chemiluminescence from the myeloperoxidase reaction. Agents Actions, 1982, 12(3), 371-376.
Wasil, M.; Halliwell, B.; Moorhouse, C.P.; Hutchison, D.C.; Baum, H. Biologically-significant scavenging of the myeloperoxidase-derived oxidant hypochlorous acid by some anti-inflammatory drugs. Biochem. Pharmacol., 1987, 36(22), 3847-3850.
Kettle, A.J.; Winterbourn, C.C. Mechanism of inhibition of myeloperoxidase by anti-inflammatory drugs. Biochem. Pharmacol., 1991, 41(10), 1485-1492.
Sayo, H.; Saito, M. The mechanism of myeloperoxidase-catalysed oxidation of aminopyrine. Xenobiotica, 1990, 20(9), 957-965.
Shacter, E.; Lopez, R.L.; Pati, S. Inhibition of the myeloperoxidase-H2O2-Cl-system of neutrophils by indomethacin and other non-steroidal anti-inflammatory drugs. Biochem. Pharmacol., 1991, 41(6-7), 975-984.
Costa, D.; Marques, A.P.; Reis, R.L.; Lima, J.L.; Fernandes, E. Inhibition of human neutrophil oxidative burst by pyrazolone derivatives. Free Radic. Biol. Med., 2006, 40, (4), 632-640.
Van Antwerpen, P.; Neve, J. In vitro comparative assessment of the scavenging activity against three reactive oxygen species of non-steroidal anti-inflammatory drugs from the oxicam and sulfoanilide families. Eur. J. Pharmacol., 2004, 496(1-3), 55-61.
Ichihara, S.; Tomisawa, H.; Fukazawa, H.; Tateishi, M.; Joly, R.; Heintz, R. Involvement of leukocytes in the oxygenation and chlorination reaction of phenylbutazone. Biochem. Pharmacol., 1986, 35(22), 3935-3939.
Van Antwerpen, P.; Prevost, M.; Zouaoui-Boudjeltia, K.; Babar, S.; Legssyer, I.; Moreau, P.; Moguilevsky, N.; Vanhaeverbeek, M.; Ducobu, J.; Neve, J.; Dufrasne, F. Conception of myeloperoxidase inhibitors derived from flufenamic acid by computational docking and structure modification. Bioorg. Med. Chem., 2008, 16(4), 1702-1720.
Tomlinson, I.D.; Iwamoto, H.; Blakely, R.D.; Rosenthal, S.J. Biotin tethered homotryptamine derivatives: high affinity probes of the human serotonin transporter (hSERT). Bioorg. Med. Chem. Lett., 2011, 21(6), 1678-1682.
Stendahl, O.; Molin, L.; Dahlgren, C. The inhibition of polymorphonuclear leukocyte cytotoxicity by dapsone. A possible mechanism in the treatment of dermatitis herpetiformis. J. Clin. Invest., 1978, 62(1), 214-220.
Bozeman, P.M.; Learn, D.B.; Thomas, E.L. Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapsone. Biochem. Pharmacol., 1992, 44(3), 553-563.
Kettle, A.J.; Gedye, C.A.; Winterbourn, C.C. Mechanism of inactivation of myeloperoxidase by 4-aminobenzoic acid hydrazide. Biochem. J., 1997, 32(Pt 2), 503-508.
Hofstra, A.H.; Li-Muller, S.M.; Uetrecht, J.P. Metabolism of isoniazid by activated leukocytes. Possible role in druginduced lupus. Drug Metab. Dispos., 1992, 20(2), 205-210.
Van Antwerpen, P.; Legssyer, I.; Zouaoui Boudjeltia, K.; Babar, S.; Moreau, P.; Moguilevsky, N.; Vanhaeverbeek, M.; Ducobu, J.; Neve, J. Captopril inhibits the oxidative modification of apolipoprotein B-100 caused by myeloperoxydase in a comparative in vitro assay of angiotensin converting enzyme inhibitors. Eur. J. Pharmacol., 2006, 537(1-3), 31-36.
Van Antwerpen, P.; Boudjeltia, K.Z.; Babar, S.; Legssyer, I.; Moreau, P.; Moguilevsky, N.; Vanhaeverbeek, M.; Ducobu, J.; Neve, J. Thiol-containing molecules interact with the myeloperoxidase/H2O2/chloride system to inhibit LDL oxidation. Biochem. Biophys. Res. Commun., 2005, 337(1), 82-88.
van Zyl, J.M.; Kriegler, A.; van der Walt, B.J. Anti-oxidant properties of H2-receptor antagonists. Effects on myeloperoxidase-catalysed reactions and hydroxyl radical generation in a ferrous-hydrogen peroxide system. Biochem. Pharmacol., 1993, 45(12), 2389-2397.
Ator, M.A.; David, S.K.; Ortiz de Montellano, P.R. Structure and catalytic mechanism of horseradish peroxidase. Regiospecific meso alkylation of the prosthetic heme group by alkylhydrazines. J. Biol. Chem., 1987, 262(31), 14954-14960.
Egan, R.W.; Hagmann, W.K.; Gale, P.H. Naphthalenes as inhibitors of myeloperoxidase: direct and indirect mechanisms of inhibition. Agents Actions, 1990, 29(3-4), 266-276.
Nassberger, L. The antihypertensive compounds hydralazine, dihydralazine and cadralazine and their metabolites inhibit myeloperoxidase activity as measured by chemiluminescence. Biochem. Pharmacol., 1991, 42(9), 1844-1847.
Hansson, A.L.; Nassberger, L. Interaction of myeloperoxidase and elastase enzyme activity with the antihypertensive agents hydralazine and dihydralazine. Pharmacol. Toxicol., 1993, 73(2), 75-78.
Jerlich, A.; Fritz, G.; Kharrazi, H.; Hammel, M.; Tschabuschnig, S.; Glatter, O.; Schaur, R.J. Comparison of HOCl traps with myeloperoxidase inhibitors in prevention of low density lipoprotein oxidation. Biochim. Biophys. Acta, 2000, 1481(1), 109-118.
Folkes, L.K.; Dennis, M.F.; Stratford, M.R.; Candeias, L.P.; Wardman, P. Peroxidase-catalyzed effects of indole-3-acetic acid and analogues on lipid membranes, DNA, and mammalian cells in vitro. Biochem. Pharmacol., 1999, 57(4), 375-382.
Jantschko, W.; Furtmuller, P.G.; Zederbauer, M.; Neugschwandtner, K.; Lehner, I.; Jakopitsch, C.; Arnhold, J.; Obinger, C. Exploitation of the unusual thermodynamic properties of human myeloperoxidase in inhibitor design. Biochem. Pharmacol., 2005, 69(8), 1149-1157.
Kettle, A.J.; Candaeis, L.P. Oxidation of tryptophan by redox intermediates of myeloperoxidase and inhibition of hypochlorous acid production. Redox. Rep., 2000, 5(4), 179-184.
Roth, A.; Ott, S.; Farber, K.M.; Palazzo, T.A.; Conrad, W.E.; Haddadin, M.J.; Tantillo, D.J.; Cross, C.E.; Eiserich, J.P.; Kurth, M.J. Inhibition of myeloperoxidase: evaluation of 2H-indazoles and 1H-indazolones. Bioorg. Med. Chem., 2014, 22(22), 6422-6429.
Rees, M.D.; Bottle, S.E.; Fairfull-Smith, K.E.; Malle, E.; Whitelock, J.M.; Davies, M.J. Inhibition of myeloperoxidase-mediated hypochlorous acid production by nitroxides. Biochem. J., 2009, 421(1), 79-86.
van Zyl, J.M.; Kriegler, A.; van der Walt, B.J. Interaction of methyl-xanthines with myeloperoxidase. An antiinflammatory mechanism. Int. J. Biochem., 1992, 24(6), 929-935.
Sliwoski, G.; Kothiwale, S.; Meiler, J.; Lowe, E.W. Jr. Computational methods in drug discovery. Pharmacol. Rev., 2014, 66(1), 334-395.
Zeng, J.; Fenna, R.E. X-ray crystal structure of canine myeloperoxidase at 3 A resolution. J. Mol. Biol., 1992, 226(1), 185-207.
Blair-Johnson, M.; Fiedler, T.; Fenna, R. Human myeloperoxidase: structure of a cyanide complex and its interaction with bromide and thiocyanate substrates at 1.9 A resolution. Biochemistry, 2001, 40(46), 13990-13997.
Zeng, J.; Fenna, R.E. X-ray crystal structure of canine myeloperoxidase at 3 Å resolution. J. Mol. Biol., 1992, 226(1), 185-207.
Davey, C.A.; Fenna, R.E. 2.3 A resolution X-ray crystal structure of the bisubstrate analogue inhibitor salicylhydroxamic acid bound to human myeloperoxidase: a model for a prereaction complex with hydrogen peroxide. Biochemistry, 1996, 35(33), 10967-10973.
Geoghegan, K.F.; Varghese, A.H.; Feng, X.; Bessire, A.J.; Conboy, J.J.; Ruggeri, R.B.; Ahn, K.; Spath, S.N.; Filippov, S.V.; Conrad, S.J.; Carpino, P.A.; Guimaraes, C.R.; Vajdos, F.F. Deconstruction of activity-dependent covalent modification of heme in human neutrophil myeloperoxidase by multistage mass spectrometry (MS(4)). Biochemistry, 2012, 51(10), 2065-2077.
Irwin, J.J.; Shoichet, B.K. ZINC-a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model., 2005, 45(1), 177-182.
Aldib, I.; Soubhye, J.; Zouaoui Boudjeltia, K.; Vanhaeverbeek, M.; Rousseau, A.; Furtmuller, P.G.; Obinger, C.; Dufrasne, F.M.; Neve, J.; Van Antwerpen, P.G.; Prevost, M. Evaluation of new scaffolds of myeloperoxidase inhibitors by rational design combined with high-throughput virtual screening. J. Med. Chem., 2012.
Doman, T.N.; McGovern, S.L.; Witherbee, B.J.; Kasten, T.P.; Kurumbail, R.; Stallings, W.C.; Connolly, D.T.; Shoichet, B.K. Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase- 1B. J. Med. Chem., 2002, 45(11), 2213-2221.
Eriksson, H.; Poewe, W. Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy. WO/2009/025618, 2009.
Ahlberg, G.; Eriksson, H. Combinations containing mpo inhibitors against neuroinflammatory disorders. WO/2009/025617, 2009.
Zarbock, A.; Polanowska-Grabowska, R.K.; Ley, K. Platelet-neutrophil-interactions: linking hemostasis and inflammation. Blood Rev., 2007, 21(2), 99-111.
van Zyl, J.M.; Basson, K.; van der Walt, B.J. The inhibitory effect of acetaminophen on the myeloperoxidase-induced antimicrobial system of the polymorphonuclear leukocyte. Biochem. Pharmacol., 1989, 38(1), 161-165.
Lojek, A.; Ciz, M.; Pekarova, M.; Ambrozova, G.; Vasicek, O.; Moravcova, J.; Kubala, L.; Drabikova, K.; Jancinova, V.; Perecko, T.; Pecivova, J.; Macickova, T.; Nosal, R. Modulation of metabolic activity of phagocytes by antihistamines. Interdisciplinary Toxicol., 2011, 4(1), 15-19.
Klebanoff, S.J.; Waltersdorph, A.M. Inhibition of peroxidase-catalyzed reactions by deferoxamine. Arch. Biochem. Biophys., 1988, 264(2), 600-606.
Matheson, N.R. The effect of antiarthritic drugs and related compounds on the human neutrophil myeloperoxidase sys tem. Biochem. Biophys. Res. Commun., 1982, 108(1), 259-265.
Cuperus, R.A.; Muijsers, A.O.; Wever, R. Antiarthritic drugs containing thiol groups scavenge hypochlorite and inhibit its formation by myeloperoxidase from human leukocytes. A therapeutic mechanism of these drugs in rheumatoid arthritis? Arthritis Rheum., 1985, 28(11), 1228-1233.
Hsuanyu, Y.; Dunford, H.B. Oxidation of clozapine and ascorbate by myeloperoxidase. Arch. Biochem. Biophys., 1999, 368(2), 413-420.
Labro, M.T.; el Benna, J.; Charlier, N.; Abdelghaffar, H.; Hakim, J. Cefdinir (CI-983), a new oral amino-2-thiazolyl cephalosporin, inhibits human neutrophil myeloperoxidase in the extracellular medium but not the phagolysosome. J. Immunol., 1994, 152(5), 2447-2455.
Ciz, M.; Komrskova, D.; Pracharova, L.; Okenkova, K.; Cizova, H.; Moravcova, A.; Jancinova, V.; Petrikova, M.; Lojek, A.; Nosal, R. Serotonin modulates the oxidative burst of human phagocytes via various mechanisms. Platelets, 2007, 18(8), 583-590.
van Zyl, J.M.; Basson, K.; Kriegler, A.; van der Walt, B.J. Mechanisms by which clofazimine and dapsone inhibit the myeloperoxidase system. A possible correlation with their anti-inflammatory properties. Biochem. Pharmacol., 1991, 42(3), 599-608.
Cuperus, R.A.; Muijsers, A.O.; Wever, R. The effect of Dpenicillamine on human myeloperoxidase, a mechanism for the efficacy of the drug in rheumatoid arthritis. Biochim. Biophys. Acta, 1983, 749(1), 18-23.
Cuperus, R.A.; Muijsers, A.O.; Wever, R. Antiarthritic drugs containing thiol groups scavenge hypochlorite and inhibit its formation by myeloperoxidase from human leukocytes. A therapeutic mechanism of these drugs in rheumatoid arthritis? Arthritis Rheum., 1985, 28(11), 1228-1233.
Zuckerman, S.H.; Bryan, N. Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL). Atherosclerosis, 1996, 126(1), 65-75.
